Update on tolvaptan for the treatment of hyponatremia

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 12, Issue 4, 2012, Pages 399-410

  Dasta, Joseph F ^a,b   Chiong, Jun R ^c   Christian, Rudell ^d   Friend, Keith ^d   Lingohr Smith, Melissa ^e   Lin, Jay ^e   Cassidy, Irving B ^d  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c LOMA LINDA UNIVERSITY   (United States)

^d OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^e Novosys Health   (United States)

Author keywords

antidiuretic hormone; arginine vasopressin; AVP receptor antagonist tolvaptan; cost effectiveness; heart failure; hyponatremia; syndrome of inappropriate antidiuretic hormone secretion; vaptans

Indexed keywords

CONIVAPTAN; DEMECLOCYCLINE; LITHIUM CARBONATE; LIXIVAPTAN; MOZAVAPTAN; PLACEBO; SATAVAPTAN; TOLVAPTAN; UREA;

ANOREXIA; ASTHENIA; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; HEALTH CARE COST; HUMAN; HYPERGLYCEMIA; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; INJECTION SITE REACTION; MORBIDITY; MORTALITY; NEPHROTOXICITY; PATHOGENESIS; PHARMACODYNAMICS; PHARMACOLOGICAL BLOCKING; POLYURIA; PREVALENCE; REVIEW; SIDE EFFECT; THIRST; XEROSTOMIA;

BENZAZEPINES; COMPARATIVE EFFECTIVENESS RESEARCH; COST-BENEFIT ANALYSIS; DRUG COSTS; HOSPITALIZATION; HUMANS; HYPONATREMIA; RECEPTORS, VASOPRESSIN; TREATMENT OUTCOME;

EID: 84866695252     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.12.30     Document Type: Review

References (61)

1. Upadhyay A, Jaber BL, Madias NE. Epidemiology of hyponatremia. Semin. Nephrol. 29(3), 227-238 (2009
2. Anderson RJ, Chung HM, Kluge R, Schrier RW. Hyponatremia: A prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann. Intern. Med. 102(2), 164-168 (1985
3. Baran D, Hutchinson TA. The outcome of hyponatremia in a general hospital population. Clin. Nephrol. 22(2), 72-76 (1984
4. Boscoe A, Paramore C, Verbalis JG. Cost of illness of hyponatremia in the United States. Cost Eff. Resour. Alloc. 4, 10 (2006
5. Callahan MA, Do HT, Caplan DW, Yoon-Flannery K. Economic impact of hyponatremia in hospitalized patients: A retrospective cohort study. Postgrad. Med. 121(2), 186-191 (2009
6. Zilberberg MD, Exuzides A, Spalding J et al. Epidemiology, clinical and economic outcomes of admission hyponatremia among hospitalized patients. Curr. Med. Res. Opin. 24(6), 1601-1608 (2008
7. Vaidya C, Ho W, Freda BJ. Management of hyponatremia: Providing treatment and avoiding harm. Cleve. Clin. J. Med. 77(10), 715-726 (2010
8. Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: Expert panel recommendations. Am. J. Med. 120(11 Suppl. 1), S1-S21 (2007
9. Esposito P, Piotti G, Bianzina S, Malul Y, Dal Canton A. The syndrome of inappropriate antidiuresis: Pathophysiology, clinical management and new therapeutic options. Nephron. Clin. Pract. 119(1), c62-c73; discussion c73 (2011
10. Hannon MJ, Thompson CJ. The syndrome of inappropriate antidiuretic hormone: Prevalence, causes and consequences. Eur. J. Endocrinol. 162(Suppl. 1), S5-S12 (2010
11. Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am. J. Med. 119(1), 71.e1-71.e8 (2006
12. Gankam Kengne F, Andres C, Sattar L, Melot C, Decaux G. Mild hyponatremia and risk of fracture in the ambulatory elderly. QJM 101(7), 583-588 (2008
13. Hoorn EJ, Rivadeneira F, van Meurs JB et al. Mild hyponatremia as a risk factor for fractures: The Rotterdam Study. J. Bone Miner. Res. 26(8), 1822-1828 (2011
14. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 73(2), 257-267 (1986
15. Chen MC, Chang HW, Cheng CI, Chen YH, Chai HT. Risk stratification of in-hospital mortality in patients hospitalized for chronic congestive heart failure secondary to non-ischemic cardiomyopathy. Cardiology 100(3), 136-142 (2003
16. Wu CC, Yeung LK, Tsai WS et al. Incidence and factors predictive of acute renal failure in patients with advanced liver cirrhosis. Clin. Nephrol. 65(1), 28-33 (2006
17. Jenq CC, Tsai MH, Tian YC et al. Serum sodium predicts prognosis in critically ill cirrhotic patients. J. Clin. Gastroenterol. 44(3), 220-226 (2010
18. Cerda-Esteve M, Ruiz-González A, Gudelis M et al. Incidence of hyponatremia and its causes in neurological patients. Endocrinol. Nutr. 57(5), 182-186 (2010
19. Doshi SM, Shah P, Lei X, Lahoti A, Salahudeen AK. Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes. Am. J. Kidney Dis. 59(2), 222-228 (2012
20. Gill G, Huda B, Boyd A et al. Characteristics and mortality of severe hyponatraemia - A hospital-based study. Clin. Endocrinol. Oxf.) 65(2), 246-249 (2006
21. Waikar SS, Mount DB, Curhan GC. Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am. J. Med. 122(9), 857-865 (2009
22. Dasta J, Amin A, Chiong J, Greenberg A, Hauptman P, Verbalis J. Impact of hyponatremia on readmission rates: Interim results from an observational, prospective, multi-center, global registry in hypervolemic and euvolemic hyponatremic patients. Pharmacotherapy 31, 337e. (2011
23. Kalra S, Efrati S, Arthur JM et al. Effect of loading dose and formulation on safety and efficacy of conivaptan in treatment of euvolemic and hypervolemic hyponatremia. Am. J. Health. Syst. Pharm. 68(7), 590-598 (2011
24. EMA. Press release. sanofi-aventis withdraws its marketing authorization application for Aquilda (satavaptan). Procedure No. EMEA/CHMP/277714/2008. EMA, London, UK (2008
25. Ghali JK, Zmily HD, Farah JO, Daifallah S. Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia. IDrugs 13(11), 782-792 (2010
26. Yamaguchi K, Shijubo N, Kodama T et al.; Ectopic ADH Syndrome Therapeutic Research Group. Clinical implication of the antidiuretic hormone (ADH) receptor antagonist mozavaptan hydrochloride in patients with ectopic ADH syndrome. Jpn. J. Clin. Oncol. 41(1), 148-152 (2011
27. Kondo K, Ogawa H, Yamashita H et al. 7-chloro-5-hydroxy-1-[2-methyl-4-(2- methylbenzoyl-amino)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): A potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist. Bioorg. Med. Chem. 7(8), 1743-1754 (1999
28. Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials. Cardiovasc. Drug Rev. 25(1), 1-13 (2007
29. Shoaf SE, Bramer SL, Bricmont P, Zimmer CA. Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide. J. Cardiovasc. Pharmacol. 50(2), 213-222 (2007
30. Shoaf SE, Bricmont P, Mallikaarjun S. Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. Br. J. Clin. Pharmacol. 73(4), 579-587 (2012
31. Shoaf SE, Elizari MV, Wang Z et al. Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias. J. Cardiovasc. Pharmacol. Ther. 10(3), 165-171 (2005
32. EMA. CHMP Assessment Report for Samsca. Procedure No. EMEA/H/C/000980. EMA, London, UK (2009
33. Schrier RW, Gross P, Gheorghiade M et al.; SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N. Engl. J. Med. 355(20), 2099-2112 (2006
34. Berl T, Quittnat-Pelletier F, Verbalis JG et al.; SALTWATER Investigators. Oral tolvaptan is safe and effective in chronic hyponatremia. J. Am. Soc. Nephrol. 21(4), 705-712 (2010
35. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J. Am. Coll. Cardiol. 46(10), 1785-1791 (2005
36. Gheorghiade M, Gottlieb SS, Udelson JE et al.; Tolvaptan Investigators. Vasopressin V(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am. J. Cardiol. 97(7), 1064-1067 (2006
37. Gheorghiade M, Gattis WA, O'Connor CM et al.; Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trial. JAMA 291(16), 1963-1971 (2004
38. Rossi J, Bayram M, Udelson JE et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: Insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Card. Care 9(2), 82-86 (2007
39. Udelson JE, Orlandi C, Ouyang J et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: An international, multicenter, randomized, placebo-controlled trial. J. Am. Coll. Cardiol. 52(19), 1540-1545 (2008
40. Konstam MA, Gheorghiade M, Burnett JC Jr et al.; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST outcome trial. JAMA 297(12), 1319-1331 (2007
41. Jaber BL, Almarzouqi L, Borgi L, Seabra VF, Balk EM, Madias NE. Short-term efficacy and safety of vasopressin receptor antagonists for treatment of hyponatremia. Am. J. Med. 124(10), 977.e1-977.e9 (2011
42. Nemerovski C, Hutchinson DJ. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: A clinical review. Clin. Ther. 32(6), 1015-1032 (2010
43. Fukunami M, Matsuzaki M, Hori M, Izumi T. Efficacy and safety of tolvaptan in heart failure patients with sustained volume overload despite the use of conventional diuretics: A Phase III open-label study. Cardiovasc. Drugs Ther. 25(Suppl. 1), 47-56 (2011
44. Matsuzaki M, Hori M, Izumi T, Fukunami M. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: A Phase III, randomized, double-blind, placebo-controlled study (QUEST Study). Cardiovasc. Drugs Ther. 25(Suppl. 1), S33-S45 (2011
45. Pang PS, Gheorghiade M, Dihu J et al. Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: Analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. Am. Heart J. 161(6), 1067-1072 (2011
46. Pang PS, Konstam MA, Krasa HB et al.; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators. Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur. Heart J. 30(18), 2233-2240 (2009
47. Shea AM, Hammill BG, Curtis LH, Szczech LA, Schulman KA. Medical costs of abnormal serum sodium levels. J. Am. Soc. Nephrol. 19(4), 764-770 (2008
48. Shorr AF, Tabak YP, Johannes RS, Gupta V, Saltzberg MT, Costanzo MR. Burden of sodium abnormalities in patients hospitalized for heart failure. Congest. Heart Fail. 17(1), 1-7 (2011
49. Cyr PL, Slawsky KA, Olchanski N et al. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. Am. J. Health. Syst. Pharm. 68(4), 328-333 (2011
50. Verbalis JG, Adler S, Schrier RW, Berl T, Zhao Q, Czerwiec FS; SALT Investigators. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur. J. Endocrinol. 164(5), 725-732 (2011
51. Chiong JR, Kim S, Lin J, Christian R, Dasta JF. Evaluation of costs associated with tolvaptan-mediated length of stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST Trial. J. Med. Econ. 15(2), 276-284 (2012
52. Dasta JF, Chiong JR, Christian R, Lin J. Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials. Hosp. Pract. (Minneap.) 40(1), 7-14 (2012
53. Fenske W, Allolio B. The syndrome of inappropriate secretion of antidiuretic hormone: Diagnostic and therapeutic advances. Horm. Metab. Res. 42(10), 691-702 (2010
54. Movig KL, Leufkens HG, Lenderink AW, Egberts AC. Validity of hospital discharge International Classification of Diseases (ICD) codes for identifying patients with hyponatremia. J. Clin. Epidemiol. 56(6), 530-535 (2003
55. Shea AM, Curtis LH, Szczech LA, Schulman KA. Sensitivity of International Classification of Diseases codes for hyponatremia among commercially insured outpatients in the United States. BMC Nephrol. 9, 5 (2008
56. Wald R, Jaber BL, Price LL, Upadhyay A, Madias NE. Impact of hospital-associated hyponatremia on selected outcomes. Arch. Intern. Med. 170(3), 294-302 (2010
57. Testani JM, Cappola TP, Brensinger CM, Shannon RP, Kimmel SE. Interaction between loop diuretic-associated mortality and blood urea nitrogen concentration in chronic heart failure. J. Am. Coll. Cardiol. 58(4), 375-382 (2011
58. Chiong JR, Cheung RJ. Loop diuretic therapy in heart failure: The need for solid evidence on a fluid issue. Clin. Cardiol. 33(6), 345-352 (2010
59. Lloyd-Jones D, Adams RJ, Brown TM et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics - 2010 update: A report from the American Heart Association. Circulation 121(7), 948-954 (2010
60. Scherz N, Labarère J, Méan M, Ibrahim SA, Fine MJ, Aujesky D. Prognostic importance of hyponatremia in patients with acute pulmonary embolism. Am. J. Respir. Crit. Care Med. 182(9), 1178-1183 (2010
61. Gheorghiade M, Rossi JS, Cotts W et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial. Arch. Intern. Med. 167(18), 1998-2005 (2007